Clinical Trial: Phase 3 Study of DWP450 in Japanese Subjects With Glabellar Lines

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07783763) titled 'Phase 3 Study of DWP450 in Japanese Subjects With Glabellar Lines' on Aug. 21.

Brief Summary: Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Glabellar Lines

Intervention: DRUG: DWP450 20 U

Clostridium botulinum Toxin type A

DRUG: 0.9% Saline Solution 0.5 mL

Normal Saline 0.5 mL

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Daewoong Pharmaceutical Co. LTD.

Disclaimer: Curated by HT Syndication....